Trials / Conditions / Hepatitis C Virus (HCV)

Hepatitis C Virus (HCV)

27 registered clinical trials studyying Hepatitis C Virus (HCV) — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool: IT Integration Process NCT07406490	University of Florida	—
Not Yet Recruiting	MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Con NCT07388979	Gardiens de Vies	—
Recruiting	Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data NCT07419347	AbbVie	—
Recruiting	California MEPS Hub NCT07433985	University of California, Los Angeles	N/A
Recruiting	Enhancing Uptake of Needle and Syringe Programs in Canadian Federal Prisons NCT07122219	McGill University Health Centre/Research Institute of the McGill University Health Centre	N/A
Completed	Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acut NCT04903626	AbbVie	Phase 3
Completed	Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C NCT04577482	AbbVie	—
Completed	Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-N NCT04352309	AbbVie	—
Completed	A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adult Particip NCT04366973	AbbVie	—
Completed	A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic NCT04189627	AbbVie	—
Completed	A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis NCT04214028	AbbVie	—
Completed	A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults NCT03219216	AbbVie	Phase 3
Completed	Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6 NCT03341871	AbbVie	—
Completed	A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive a NCT03222583	AbbVie	Phase 3
Completed	Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced NCT03235349	AbbVie	Phase 3
Completed	A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New NCT03201718	AbbVie	—
Completed	Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and NCT03212521	AbbVie	Phase 3
Completed	A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) NCT03089944	AbbVie	Phase 3
Completed	A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Vir NCT03069365	AbbVie	Phase 3
Completed	A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjec NCT03067129	AbbVie	Phase 2 / Phase 3
Completed	A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infectio NCT02966795	AbbVie	Phase 3
Completed	Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chroni NCT02609659	AbbVie	Phase 3
Completed	Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic H NCT02487199	AbbVie	Phase 3
Completed	ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Ci NCT02517515	AbbVie	Phase 3
Completed	Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects Wit NCT01754974	Bristol-Myers Squibb	Phase 3
Completed	Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated I NCT01616524	Bristol-Myers Squibb	Phase 3
Withdrawn	Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in S NCT01447394	Bristol-Myers Squibb	Phase 3